BioNTech Stock Options Expiring on 21st of February
| BNTX Stock | USD 123.77 2.89 2.39% |
BioNTech's latest option contracts expiring on February 21st 2025 are carrying combined implied volatility of 0.61 with a put-to-call open interest ratio of 0.57 over 41 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on February 21st 2025. The total put volume is at 15.0, with calls trading at the volume of 75.0. This yields a 0.2 put-to-call volume ratio.
Open Interest Against February 21st 2025 Option Contracts
BioNTech option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in BioNTech's lending market. For example, when BioNTech's puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on BioNTech, he or she must hedge the risk by shorting BioNTech stock over its option's life.
2025-02-21
The chart above shows BioNTech's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. BioNTech's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for BioNTech's option, there is no secondary market available for investors to trade.
BioNTech Maximum Pain Price Across 2025-02-21 Option Contracts
Max pain occurs when BioNTech's market makers reach a net positive position across all BioNTech's options at a strike price where option holders stand to lose the most money. By contrast, BioNTech's option sellers may reap the most after selling more options than buying, causing them to expire worthless.
BioNTech SE In The Money Call Balance
When BioNTech's strike price is surpassing the current stock price, the option contract against BioNTech SE stock is said to be in the money. When it comes to buying BioNTech's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on BioNTech SE are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
BioNTech Current Options Market Mood
BioNTech's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps BioNTech Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most BioNTech's options investors are not very successful. BioNTech's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current BioNTech contract
Base on the Rule 16, the options market is currently suggesting that BioNTech SE will have an average daily up or down price movement of about 0.0381% per day over the life of the 2025-02-21 option contract. With BioNTech trading at USD 123.77, that is roughly USD 0.0472. If you think that the market is fully incorporating BioNTech's daily price movement you should consider buying BioNTech SE options at the current volatility level of 0.61%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
BioNTech |
BioNTech Option Chain
When BioNTech's strike price is surpassing the current stock price, the option contract against BioNTech SE stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
BioNTech's option chain is a display of a range of information that helps investors for ways to trade options on BioNTech. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for BioNTech. It also shows strike prices and maturity days for a BioNTech against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | BNTX250221C00085000 | 2 | 85.0 | 36.5 - 41.3 | 28.64 | In |
Call | BNTX250221C00090000 | 7 | 90.0 | 31.8 - 35.9 | 24.32 | In |
Call | BNTX250221C00095000 | 11 | 95.0 | 27.0 - 30.6 | 20.5 | In |
Call | BNTX250221C00100000 | 26 | 100.0 | 21.9 - 25.7 | 22.8 | In |
Call | BNTX250221C00105000 | 2 | 105.0 | 17.1 - 20.8 | 17.9 | In |
Call | BNTX250221C00110000 | 22 | 110.0 | 13.1 - 15.9 | 14.5 | In |
Call | BNTX250221C00115000 | 129 | 115.0 | 9.6 - 11.5 | 10.3 | In |
Call | BNTX250221C00120000 | 1192 | 120.0 | 6.5 - 9.1 | 5.8 | In |
Call | BNTX250221C00125000 | 403 | 125.0 | 3.6 - 6.0 | 3.79 | Out |
Call | BNTX250221C00130000 | 1005 | 130.0 | 2.05 - 3.0 | 2.75 | Out |
Call | BNTX250221C00135000 | 861 | 135.0 | 0.95 - 1.5 | 1.26 | Out |
Call | BNTX250221C00140000 | 290 | 140.0 | 0.6 - 0.85 | 0.8 | Out |
Call | BNTX250221C00145000 | 228 | 145.0 | 0.35 - 2.45 | 0.54 | Out |
Call | BNTX250221C00150000 | 75 | 150.0 | 0.05 - 2.35 | 0.25 | Out |
Call | BNTX250221C00155000 | 81 | 155.0 | 0.05 - 1.45 | 0.2 | Out |
Call | BNTX250221C00160000 | 35 | 160.0 | 0.0 - 2.2 | 0.23 | Out |
Call | BNTX250221C00165000 | 1 | 165.0 | 0.0 - 2.2 | 0.65 | Out |
Call | BNTX250221C00170000 | 5 | 170.0 | 0.0 - 2.15 | 0.6 | Out |
Call | BNTX250221C00175000 | 25 | 175.0 | 0.0 - 2.15 | 0.2 | Out |
Call | BNTX250221C00180000 | 0 | 180.0 | 0.0 - 0.75 | 0.75 | |
Put | BNTX250221P00070000 | 6 | 70.0 | 0.0 - 2.15 | 0.09 | Out |
Put | BNTX250221P00085000 | 13 | 85.0 | 0.0 - 2.15 | 0.3 | Out |
Put | BNTX250221P00090000 | 47 | 90.0 | 0.0 - 0.75 | 0.18 | Out |
Put | BNTX250221P00095000 | 41 | 95.0 | 0.1 - 0.15 | 0.12 | Out |
Put | BNTX250221P00100000 | 460 | 100.0 | 0.05 - 0.6 | 0.33 | Out |
Put | BNTX250221P00105000 | 753 | 105.0 | 0.25 - 0.45 | 0.28 | Out |
Put | BNTX250221P00110000 | 850 | 110.0 | 0.25 - 0.85 | 1.04 | Out |
Put | BNTX250221P00115000 | 181 | 115.0 | 1.0 - 1.75 | 1.8 | Out |
Put | BNTX250221P00120000 | 56 | 120.0 | 2.05 - 3.3 | 3.46 | Out |
Put | BNTX250221P00125000 | 24 | 125.0 | 3.2 - 5.7 | 5.4 | In |
Put | BNTX250221P00130000 | 76 | 130.0 | 6.0 - 9.0 | 11.0 | In |
Put | BNTX250221P00135000 | 1 | 135.0 | 10.8 - 14.5 | 14.6 | In |
Put | BNTX250221P00140000 | 0 | 140.0 | 15.3 - 19.0 | 15.3 | In |
Put | BNTX250221P00145000 | 0 | 145.0 | 20.0 - 23.2 | 20.0 | In |
Put | BNTX250221P00150000 | 0 | 150.0 | 24.9 - 28.6 | 24.9 | In |
Put | BNTX250221P00155000 | 0 | 155.0 | 29.8 - 33.6 | 29.8 | In |
Put | BNTX250221P00160000 | 0 | 160.0 | 34.9 - 38.1 | 33.28 | In |
Put | BNTX250221P00165000 | 0 | 165.0 | 39.9 - 43.5 | 39.9 | In |
Put | BNTX250221P00170000 | 0 | 170.0 | 44.5 - 48.6 | 44.5 | In |
Put | BNTX250221P00175000 | 0 | 175.0 | 49.2 - 54.0 | 48.01 | In |
Put | BNTX250221P00180000 | 0 | 180.0 | 54.2 - 59.0 | 54.2 | In |
BioNTech Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
BioNTech Total Stockholder Equity
Total Stockholder Equity |
|
BioNTech Corporate Management
| Katalin Kariko | Senior Therapies | Profile | |
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | Vice Strategy | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Siegbert Kloos | Datand Digital | Profile | |
| Sierk Poetting | COO MD | Profile |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.